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Abstract
Objective: To assess the use of oral iron, intravenous (IV) iron, and erythropoiesis-stimulating agents (ESAs) for the
prevention and management of perioperative anemia in elective orthopedic surgery patients, and to provide a clinical
algorithm for use. Data Sources: A PubMed and MEDLINE search was conducted from 1964 through March 2016 using
the following search terms alone or in combination: orthopedic, surgery, elective, anemia, blood transfusion, iron, erythropoiesisstimulating agents, and erythropoietin. Study Selection and Data Extraction: All English-language prospective and
retrospective human studies and meta-analyses evaluating oral iron, IV iron, or ESA alone or in combination in elective
orthopedic surgery patients were evaluated, provided they reported blood transfusion outcomes. Data Synthesis: A
total of 9 prospective and retrospective studies and 1 meta-analysis were identified and included. In the preoperative
setting, administration of oral iron, IV iron, or ESA alone or in combination to correct underlying anemia led to significantly
reduced transfusion rates. Transfusion requirements were generally less with combination therapy (ESA + oral or IV
iron). In the short-term perioperative or postoperative period, use of oral or IV iron led to conflicting results, with
some reporting a statistically significant reduction in blood transfusions, whereas others reported none. Conclusions: In
elective orthopedic surgery, IV or oral iron with or without an ESA may provide benefit in prevention of postoperative
anemia and results in blood transfusion reduction without significantly increasing the risk of adverse events. These agents
should be considered at the lowest effective dose with emphasis on administration prior to planned surgery.
Keywords
blood transfusion, anemia, elective orthopedic surgery, iron, erythropoiesis-stimulating agent

Introduction
Postoperative anemia is a common complication in patients
undergoing major orthopedic surgery, including elective
total hip arthroplasty (THA) and total knee arthroplasty
(TKA). Postoperative anemia is associated with postoperative infections, poor physical function and recovery, and
increased length of hospital stay and mortality.1 The prevalence of anemia at baseline in adults 65 years or older is
11% for men and 10.2% for women, potentially leading to a
higher rate of underlying anemia prior to elective surgery
because of a greater incidence of THA and TKA in the
elderly population.2,3 In patients undergoing elective THA
or TKA, the prevalence of preoperative anemia is approximately 24.9% ± 9%, with estimations of subsequent postoperative anemia at 51% ± 10%.1 The pervasiveness of
perioperative anemia in this patient population increases the
risk for postoperative complications.
Anemia in elective orthopedic surgery is multifactorial.
A major contributing factor related to surgery itself is

intraoperative blood loss, which may be as significant as1
to 2 L during the procedure.4 The acute blood loss during
surgery and subsequent decline in oxygen delivery to vital
tissues is often unable to be corrected by the red blood cell
(RBC) maturation process, which typically takes 1 to 2
weeks.5,6 Anemia may also arise as a result of a postoperative inflammatory response. This leads to decreased erythropoietin (EPO) production or response inhibition, even
with normal levels of circulating EPO. The inflammatory
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Table 1. Negative Outcomes Associated With Blood
Transfusions.12,14,15
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Increased length of hospital stay
Increased rate of discharge to an inpatient facility
Worse surgical and medical outcomes
Allergic reactions
Transfusion-related acute lung injury
Transfusion-associated circulatory overload
Venous thromboembolism
Graft versus host disease
Immunosuppression
Postoperative infections

response has the potential to modify iron metabolism and
decrease the body’s ability to utilize iron stores.7-9 Each
pathway to the development of postoperative anemia must
be considered when evaluating potential treatment strategies. Additionally, certain risk factors or patient demographics have been identified as predictors for postoperative
anemia in the overall surgery population. These include
female sex, smaller body surface area, and African American
racial identity.10,11 Regardless, all patients should be
screened for anemia preoperatively and throughout the surgical setting.
Correction of postoperative anemia has historically been
focused on blood transfusions. Orthopedic surgery alone
accounts for 10% of all packed RBC transfusions nationwide.12
A recent observational study at a large hospital network
found transfusion rates of 19.3% and 38.5% in patients
undergoing TKA and THA, respectively, with considerable
variation among surgeons.13 With blood transfusions come
numerous complications, culminating in a high incidence of
morbidity and mortality.12,14 From 2008 to 2012, 198
transfusion-related mortalities were reported to the US
Food and Drug Administration.12 Blood transfusions pose
an increased burden on the health care system and are associated with a number of complications and poor outcomes,
which are listed in Table 1.12,14,15 In addition to various
complications, there is also considerable monetary cost
associated with transfusions. An evaluation of allogenic
blood transfusions in patients undergoing elective THA
found that transfusions increased total cost for patients by
$1731 ± $49 compared with patients who did not receive
transfusions (P < 0.001).15
Various approaches have been studied to reduce the use
of blood transfusions to prevent transfusion-related adverse
events, increase patient safety, and reduce cost. The
American Association of Blood Banks (AABB) published
clinical practice guidelines in 2012 evaluating transfusion
thresholds in hospitalized patients.16 For postoperative surgical patients who are otherwise stable, including those
with a preexisting cardiovascular condition, the AABB recommends a traditional transfusion threshold of 8 g/dL or

less or as needed when symptoms (chest pain, orthostatic
hypotension, tachycardia unresponsive to fluid resuscitation, or heart failure) arise. Overall, this strategy is associated with 39% fewer transfusions, with improved morbidity
and mortality and no difference in efficacy.16 Beyond a
transfusion threshold, additional strategies can aid in correcting anemia and further mitigate the need for transfusion,
such as the use of intravenous (IV) or oral iron therapy or
erythropoiesis-stimulating agents (ESAs).
To date, there is no standard of care in perioperative
management of anemia in patients undergoing elective
THA or TKA. In this article, we discuss various approaches
to minimize blood transfusions in patients undergoing elective orthopedic surgery, focusing on the role of IV and oral
iron and ESA pharmacotherapy, as well as important treatment considerations for the use of these agents.

Methods
An English-language literature review was performed
through a PubMed and MEDLINE database search from
1964 through March 2016 using the following terms alone
or in various combinations: orthopedic, surgery, elective,
anemia, blood transfusion, iron, erythropoiesis-stimulating
agents, and erythropoietin. Additionally, references of relevant articles were reviewed for additional studies.

Results
A total of 8 prospective and retrospective studies and 1
meta-analysis evaluating strategies to limit blood transfusions in elective orthopedic surgeries in adult patients were
included in the review.

Prehospitalization Setting
Emphasis should be placed on prevention, prompt identification, and correction of anemia in patients undergoing
elective orthopedic surgery. Several strategies have been
evaluated to achieve this in the preoperative setting.
Initially, patients should be instructed to discontinue antiplatelet, anticoagulant, and NSAID (nonsteroidal antiinflammatory drug) medications prior to surgery. Patients
with planned elective surgeries should be screened for
underlying anemia as soon as possible.12,17 Iron replacement and ESAs have been studied preoperatively as a way
of preemptively correcting anemia.
Preoperative iron-deficiency anemia (IDA) has been
shown to increase transfusion requirements in the cardiac
surgery population and remains a concern in various types
of surgical populations.18 Correcting IDA preoperatively
through the use of oral or IV iron may be of benefit, especially in the elective orthopedic surgery population where
there is ample time to correct preoperative anemia.19 Oral

Downloaded from aop.sagepub.com at BUTLER UNIV on May 11, 2016

3

Steuber et al
iron is typically preferred over IV iron; however, IV iron is
indicated for patients who cannot tolerate oral iron; those
who are experiencing persistent iron losses; patients receiving EPO; those with iron malabsorption issues, including
short bowel syndrome; and patients with a short timeline
before surgery.
Oral iron is best suited for planned TKA or THA surgeries when preoperative anemia is identified ahead of time,
noting that oral iron takes 3 to 6 months to fully replete
stores.4 One study assessed oral iron (formulation and doses
not specified) given for a mean of 24.5 weeks preoperatively in orthopedic patients with hemoglobin concentrations less than 12 g/dL. Of the 26 patients identified, 24
(92%) were female; the average age was 67 years; and all
were undergoing primary THA. Patients responding with
improved hemoglobin concentrations greater than 12 g/dL
demonstrated lower transfusion rates than those who did
not respond (9% of responders [n = 1 of 11] compared with
33% of nonresponders [n = 5 of 15]; P < 0.05).20 Additional
labs such as ferritin and transferrin saturation were not
reported, making it difficult to identify underlying iron deficiency. Challenges to administering oral iron preoperatively
include proper identification of IDA several months in
advance of planned surgeries and patient adherence to oral
iron repletion (Figure 1).
IV iron may be indicated in patients for whom quick
repletion of stores is desired, such as patients found to have
IDA in the perioperative setting.21 However, the convenience of administering higher doses over a shorter period
of time may be offset by concern for hypersensitivity reactions, which although rare, may be life-threatening.22
Although IV iron provides more timely repletion than oral
iron, no studies evaluating IV iron alone within the preoperative setting were identified.
Use of an ESA, in tandem with oral or IV iron, may help
increase circulating erythrocytes and improve perioperative outcomes.23,24 A recent meta-analysis highlighted
results from 26 trials encompassing 3560 orthopedic
patients receiving an ESA, with or without iron. Of the trials included, 96% (n = 25) combined ESA and iron therapy,
whereas 35% (n = 9) combined ESA, iron, and preoperative autologous blood donation. All patients included in
this analysis underwent elective TKA or THA. The ESA
dosing, schedule, and duration varied among the clinical
trials, and 20 trials included in the analysis involved participant weight and ESA dosing. Globally, doses ranged
from 225 IU/kg/wk to 2100 IU/kg/wk, with the most consistent dosing regimen of epoetin alfa at 600 IU/kg/wk.
Most frequently, patients were initiated on therapy from 7
to 35 days prior to procedure, with the most common starting date cited at 21 days preoperatively (13 trials).
Administration continued anywhere from 0 to 7 days prior
to procedure, although continuation of ESA dosing postoperatively was rarely seen.23

Five trials used an ESA with IV iron, 2 included a combination of IV and oral, and the remaining used oral iron supplementation. Commonly, oral iron was initiated at the time
of epoetin alfa; however, 1 trial did initiate oral iron 2 weeks
prior to epoetin alfa. Regardless of dose and duration, use of
oral iron in conjunction with epoetin alfa led to mixed results
with respect to transfusion requirements. The combination of
oral iron and epoetin alfa never resulted in more transfusions;
however, when study protocols allowed for an iron-alone
arm, these patients often required more blood transfusions
than those in the combination arm. Administration of IV iron,
as compared with oral iron, did not alter these findings.
Though the details included in the analysis were not
fully described in the article, the authors noted that use of
ESAs led to higher hemoglobin concentrations at discharge.
This finding did not reach statistical significance and was
not adjusted for iron administration, baseline hemoglobin
values, or postoperative differences in hemoglobin. As a
safety end point for the meta-analysis, thromboembolic
events were reviewed. The authors found no difference in
thromboembolic risk when using an ESA; however, minimal data were provided about use of venous thromboembolism prophylaxis. The findings from this meta-analysis
suggest that ESA use may provide modest benefits in reducing transfusion rates in the short-term preoperative setting,
without an increase in adverse events. Interestingly, these
results are further supported by a recent prospective study
demonstrating a 10% absolute reduction in transfusions (24
[13%] vs 5 [3%]; P = 0.0003) after implementation of a
protocol utilizing ESA + IV iron in anemic preoperative and
perioperative patients.24 Allotment of 3 to 4 weeks preoperatively is necessary to allow the full effects of ESA
administration to be seen. If used, ESAs should be given
with iron to maximize the benefit (Figure 1).

Intraoperative Setting
Although outside the scope of this review, numerous interventions have been studied in the intraoperative setting to
reduce the need for blood transfusions in orthopedic surgery.
These consist of nonpharmacological and pharmacological
strategies. Nonpharmacological modalities include normovolemic hemodilution, hypotensive anesthesia, tourniquets,
bipolar sealants, and Cell Saver. Of these, the use of regional
and hypotensive anesthesia has the most promising results.12
Pharmacological strategies include fibrin sealants, desmopressin, thrombin, epinephrine or norepinephrine lavage,
ε-aminocaproic acid, and tranexamic acid (TXA). To date,
TXA, administered locally or systemically (IV), has the
most robust data to support intraoperative use; however, any
strategy used should be in tandem with preoperative assessment to augment transfusion reduction.12,25 Local and systemic (IV) administration of TXA are both effective
techniques, without an increased rate of complications.
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Figure 1. Proposed algorithm for identification and correction of perioperative anemia in elective orthopedic surgery patients.
Abbreviations: ESA, erythropoiesis-stimulating agent (epoetin alfa); Hgb, hemoglobin; IV, intravenous; MCV, mean corpuscular volume.
a
Refer to Table 2 for specific dosing recommendations.
b
American Association of Blood Banks recommends restrictive transfusion for Hgb <8 mg/dL or symptomatic anemia.
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Perioperative Setting
IV iron repletion alone has been evaluated in orthopedic
surgery in the perioperative setting, including the immediate preoperative and postoperative periods, for the past
decade. The iron formulation primarily utilized is iron
sucrose; however, ferric carboxymaltose has also been
used. No standard dose exists in this setting; however, total
doses of 200 to 600 mg of iron sucrose (100-200 mg every
48 hours for 2-3 doses beginning on the day of admission)
perioperatively have been reported in studies focusing on
IV iron.26-31 Studies typically did not report baseline iron
labs; however, 1 trial specified that patients had nearnormal iron levels (46.3-53.2 µg/dL), with no significant
difference between groups as well as normal ferritin and
transferrin levels.26 No difference has been shown in blood
transfusion rates (percentage of patients receiving a transfusion) in studies that compared patients receiving IV iron
alone administered throughout the preoperative and postoperative periods with patients not receiving iron.26-28
Conversely, a retrospective study focusing only on postoperative IV iron administration found that its use significantly reduced the percentage of patients receiving a
transfusion (11.5% vs 26.4%, P = 0.001).29 These findings
are further complicated by subanalyses of 2 of the aforementioned trials showing that patients with preoperative
hemoglobin concentrations greater than 12 g/dL required
fewer transfusions compared with those in control
groups.26,27 This indicates that the ability of IV iron monotherapy to maintain hemoglobin concentrations above
transfusion thresholds may be limited in the short-term setting when patients have lower baseline hemoglobin.
In addition to IV iron, postoperative oral iron has been
evaluated. One study assessed patients with normal iron
stores who were treated with oral iron therapy (ferrous sulfate 325 mg 4 times daily) or placebo, starting postoperative
day 2 for the duration of their hospitalization.32 No difference in transfusion rates or hemoglobin concentrations was
noted between groups, likely because of the length of time
it takes to see effects with oral therapy. Additionally, neither
group experienced a hastened recovery of hemoglobin concentrations, and both had similar increases in reticulocyte
fractions. This study did not assess other outcomes associated with postoperative anemia. IV iron may be preferred in
the acute perioperative setting because it may allow rapid
administration and use of iron despite the presence of
inflammatory processes, which mitigate the body’s ability
to utilize iron stores.

Discussion
A focus on limiting blood transfusions secondary to postoperative anemia in elective orthopedic surgery patients is
essential to improve patient outcomes. Measures can be

taken to reduce blood transfusions after elective orthopedic
surgery, including preoperative screening and treatment of
underlying anemia and use of iron or ESAs to improve perioperative anemia.
Postoperative anemia is easily explained by acute blood
loss and the inflammatory state induced by surgery itself,
leading to altered erythropoiesis and iron metabolism, and
reduced availability of iron when the body attempts to compensate. In patients undergoing elective THA or TKA, the
goal of limiting blood transfusions begins in the preoperative period, where screening and assessment are crucial.
The Network for Advancement of Transfusion Alternatives
(NATA) recommends that screening and correction of preoperative anemia take place 28 days or more prior to
surgery.3 As erythropoiesis and iron play an important role,
strategies to overcome perioperative anemia include the use
of iron and ESAs. If patients are found to be iron deficient,
oral iron replacement is adequate in treating this underlying
deficiency, provided there is adequate time prior to surgery.
IV iron should be reserved for patients in whom oral therapy is not indicated. If patients have deficiencies in folate or
vitamin B12, these should also be treated prior to surgery.
For patients who do not respond to iron and those without
nutritional deficiencies, ESA therapy may be implemented
to correct the anemia. Regardless of the plan for preoperative autologous blood donation, the combination of IV iron
and epoetin alfa has demonstrated the most favorable results
when used in patients with preoperative anemia and should
be considered in patients not responding to ESA therapy
alone.
Agents used and dosing strategies varied throughout the
literature; however, appropriate dosing for each of the
agents used should be applied and may be institution specific. Table 2 outlines evidence-supported agents, dosing
utilized, and estimated time to peak effect. Institution formulary and infusion protocols typically dictate which iron
formulation is used and how it is given. Regarding ESA
dosing, the literature and clinical trials suggest a preoperative hemoglobin level of 10 to 13 g/dL as a trigger for ESA
therapy, but expected blood loss should also play a role in
the decision to use an ESA.23 To date, clinical trials have
only used epoetin alfa; however, darbepoetin alfa may offer
the advantage of a pre-filled syringe alternative. Darbepoetin
alfa also has a 3-fold longer half-life than epoetin alfa and
may be dosed less frequently.33 Nevertheless, clinical benefits of darbepoetin alfa in the setting of elective orthopedic
surgery remain to be evaluated.
Although the agents discussed are being evaluated for
short-term use, adverse events are important to consider.
Oral iron commonly causes constipation, dark stools, stomach irritation, and nausea. Additionally, to maximize absorption, oral iron needs an acidic environment and should be
taken on an empty stomach or with an acidifier such as vitamin C, which further increases some gastrointestinal adverse

Downloaded from aop.sagepub.com at BUTLER UNIV on May 11, 2016

6

Annals of Pharmacotherapy 

Table 2. Summary of Iron and ESA Dosing and Expected Time to Peak Effect for the Correction of Perioperative Anemia.
Agent
Ferrous sulfate (po)
Iron sucrose (IV)
Ferric carboxymaltose (IV)
Epoetin alfa (sc)

Suggested Dosing Based on Clinical Trialsa

Expected Time to Peak Effect

b

3 To 6 Monthsc
2 To 4 weekse

325 mg twice to thrice daily
•• Preoperative with ESA: 200 mg once when ESA given
•• Perioperative: 100-200 mg every 48 hours for 2-3
dosesd during hospital admission
600 mg onced
600 IU/kg/wkf

2 To 4 weekse
2 To 4 weekse

Abbreviations: ESA, erythropoiesis-stimulating agent (epoetin alfa); Hgb, hemoglobin; IV, intravenous.
a
Dosing schemes varied widely across clinical trials; minimum total effective doses should be utilized.
b
Started 3 to 6 months prior to planned surgery.
c
May see some effect within 3 weeks.
d
Started on day of admission, consider equivalent formulary IV iron.
e
May see some effect within 2 to 7 days.
f
Single or repeat doses may be warranted; close Hgb monitoring required; consider equivalent formulary ESA.

effects. Another consideration in postoperative patients and
some preoperative patients is that many would also be
receiving opioids for pain relief, which may compound constipation in patients receiving oral iron. IV iron is most notably associated with hypersensitivity reactions, including
anaphylaxis; however, this is more common with older formulations or fast rates of administration. Other possible
adverse events include hypotension, headache, nausea, and
muscle cramps.22 In orthopedic surgery studies, no differences were found between IV iron and comparators with
regard to adverse events, and no severe adverse reactions to
IV iron were noted.
ESAs are also associated with risks, most notably a
boxed warning for cardiovascular events, including thromboembolic events. Aggressive venous thromboembolism
prophylaxis following orthopedic surgeries should always
be done, especially when using ESAs perioperatively. Other
possible adverse effects include allergic reactions, hypertension, and gastrointestinal effects, including nausea and
vomiting. With ESA use, weekly hemoglobin values should
be monitored for rapid changes in concentrations and to
assess the need for changes in dosing or frequency. If hemoglobin concentrations reach 13 mg/dL for men or 12 mg/dL
for women, ESA therapy should be discontinued.3 ESAs
should be used with caution in chronic kidney disease and
oncology patients. These patients are at higher risk of
thromboembolic events and may have a lower threshold for
ESA discontinuation (hemoglobin 10 to 11 mg/dL).34 Iron
deficiency, chronic inflammation, and underlying malignancy diminish response to ESAs. Iron studies should be
completed prior to ESA use, and deficiencies should be
corrected.
Finally, cost often accompanies agent selection, with
oral iron as the least-expensive option, followed by IV iron,
and then ESAs. A recent analysis demonstrated a reduction
in blood transfusions with ESA therapy; however, use of
ESAs in this analysis proved cost-prohibitive. ESA use was

associated with an increased cost per patient of €785
(roughly US $860) and more than €7000 (roughly US
$7650) per unit of blood transfusion avoided. Although the
authors speculated that this could be partly a result of the
strict transfusion protocol in place at their institution, careful cost considerations must be evaluated prior to ESA
use.35 IV iron, on the other hand, may be associated with
neutral costs or modest cost savings, as demonstrated by
one study.29 This can likely be attributed to the fact that IV
iron significantly reduced the percentage of patients transfused in this study.
Multiple facets should be evaluated when considering
the use of oral or IV iron or an ESA to reduce blood transfusions in orthopedic surgery patients. The studies
reviewed were limited by nonstandardized dosing, differences in timing of therapy initiation, and mixed reports of
efficacy. Based on understanding of drug mechanisms and
onset of action, pathophysiology of anemia, and available
evidence, an assessment of findings and a proposed treatment algorithm is outlined in Figure 1, with dosing strategies outlined in Table 2. This algorithm is designed to
serve only as a guide; clinical considerations, patientspecific factors, and individualized dosing should be evaluated. In addition to iron and ESAs, additional measures
should be taken to reduce transfusions, including cessation of antiplatelet and anticoagulant medications prior to
planned surgery and intraoperative strategies such as local
or systemic TXA. Finally, strict transfusion protocols
should be in place according to AABB guidelines (hemoglobin <8 g/dL or symptoms present) because they have
been shown to reduce transfusion rates and potentially
reduce mortality. With careful planning and strategic
implementation of interventions such as iron supplementation and use of ESAs, blood transfusions can be minimized in patients undergoing elective orthopedic surgery,
leading to reduced hospital cost and improved patient
outcomes.
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